News
05-13-2011, 04:32 AM
ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate.
More... (http://www.news-medical.net/news/20110513/ZIOPHARM-submits-IND-with-FDA-for-Ad-RTS-IL-12-Phase-I-study-in-cancer.aspx)
More... (http://www.news-medical.net/news/20110513/ZIOPHARM-submits-IND-with-FDA-for-Ad-RTS-IL-12-Phase-I-study-in-cancer.aspx)